Why I Structure My Healthcare Portfolio Like a VC Fund
The maths behind owning 15-25 mispriced healthcare companies
To read our full disclaimer, click here.
Venture capitalists understand something most public market investors miss completely.
It’s not about being right on every bet. It’s about structuring a portfolio where the winners can more than compensate for the losers.
That’s asymmetry.
And it’s the foundation of how I think about building a healthcare portfolio.
The Portfolio Maths
A top-tier VC fund invests in 30 companies expecting the majority to fail or return modest capital. They’re not being pessimistic. They’re being realistic.
Even with rigorous due diligence, even with decades of pattern recognition, even with board seats and hands-on involvement - most investments don’t become home runs.
But here’s the insight: they don’t need to.
If 3 out of 30 deliver 10-50x returns, the fund crushes it. The winners pay for all the losers and then some. The portfolio succeeds even though most individual positions didn’t.
This isn’t reckless gambling. It’s disciplined maths.
Applying This to Microcap Healthcare
A portfolio built this way might hold 15-25 positions across different types of healthcare optionality.
A few diagnostic companies with novel tests and regulatory catalysts ahead. A couple of rare disease plays with differentiated platforms. Some healthcare services businesses with recurring revenue and operating leverage potential. Maybe a medical device company entering new markets or a healthcare IT infrastructure play the market hasn’t noticed.
Each represents a different type of optionality. Clinical. Regulatory. Commercial. M&A. The portfolio is diversified across how value could be unlocked - not just across ticker symbols.
Some won’t work. Maybe 8 or 10 are flat or down meaningfully over time because things didn’t work out.
But if 4 or 5 deliver 5-10x returns? The portfolio wins decisively.
I don’t need every position to work. I need to find enough quality setups with genuine asymmetry that the portfolio maths compound in my favour over time.
This Only Works With Quality
Here’s where I differ from the spray-and-pray crowd.
The VC portfolio structure only works if the underlying bets are good. A portfolio of garbage is still garbage - no amount of clever structuring fixes that.
Every company I cover in The Clinical Edge has to clear a quality bar before I think about portfolio fit:
Actual competitive advantages - regulatory moats, switching costs, technical expertise
Management with real skin in the game
Balance sheets that can survive setbacks
Multiple ways to win - platform optionality, not single-product dependence
These aren’t moonshots. They’re businesses. The asymmetry comes from the market’s failure to properly value what’s already there - not from hoping something speculative hits.
A healthcare infrastructure company with 95% customer retention and a new product generating 3x revenue per unit isn’t a lottery ticket. It’s a quality business trading at a discount because it’s small and overlooked.
Why Microcap Healthcare Is Perfect for This Approach
Healthcare has structural characteristics that make VC-style portfolio construction particularly effective.
The complexity screens out generalists. FDA pathways, reimbursement dynamics, clinical data interpretation - most investors don’t have the knowledge, so they stay away or misprice what they see.
The binary catalysts create fear. Upcoming regulatory decisions make stocks “too risky” for conservative capital - even when the underlying business is solid.
The market cap constraints are real for micro-cap companies. Institutions can’t own a £50m company. The natural buyer base is limited, creating persistent undervaluation.
The Bottom Line
Most investors judge themselves on individual stock picks. Did this one work? Was I right about that one?
I think about it differently. I’m building a portfolio where the structure itself creates edge - where I can be wrong on some positions and still generate strong returns because the winners have room to run.
That requires two things: quality businesses worth owning, and enough asymmetry in the setups that winners can compensate for losers.
That’s my approach.
Thanks for reading,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.